Oncologia
Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers
Scritto da Annals of Oncology - recent issues   
OncologiaBackground

RET rearrangements are targetable, oncogenic lung cancer drivers. While previous series have shown durable clinical benefit with pemetrexed-based therapies in ALK- and ROS1-rearranged lung cancers, th ... ...

 
Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer
Scritto da Annals of Oncology - recent issues   
OncologiaBackground

In the phase I KEYNOTE-001 study, pembrolizumab demonstrated durable antitumor activity in patients with advanced non-small-cell lung cancer (NSCLC). We sought to characterize the relationship between pembrolizumab dose, ... ...

 
Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular C
Scritto da Annals of Oncology - recent issues   
OncologiaBackground

The purpose of the protocol was to reduce the treatment burden in clinical stage I (CSI) seminoma by offering risk-adapted treatment. The protocol aimed to prospectively validate the proposed risk factors for relapse, str ... ...

 
Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell
Scritto da Annals of Oncology - recent issues   
OncologiaBackground

Emerging agents blocking the programmed cell death 1 (PD-1) pathway show activity in metastatic clear cell renal cell carcinoma (mRCC). The aim of this study was to evaluate the efficacy and safety of vascular endothelial ... ...

 
Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment
Scritto da Annals of Oncology - recent issues   
OncologiaBackground

Fibroblast growth factor receptor 3 (FGFR3) is an actionable target in bladder cancer. Preclinical studies show that anti-FGFR3 treatment slows down tumor growth, suggesting that this tyrosine kinase receptor is a candida ... ...

 
Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes
Scritto da Annals of Oncology - recent issues   
OncologiaBackground

Brentuximab vedotin (BV) is a key therapeutic agent for patients with relapsed/refractory classical Hodgkin lymphoma (cHL). The outcomes of patients experiencing disease progression after BV are poorly described.

... continua Aggiungi commento
 
Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL
Scritto da Annals of Oncology - recent issues   
OncologiaBackground

Histologically, follicular lymphoma (FL) grades 1, 2 and 3A are composed of two distinct cell types, centroblasts and centrocytes. FL grade 3B is composed only of centroblasts and has been shown to differ in immunophenoty ... ...

 
Inizio Prec. 1 2 3 4 5 6 7 8 9 10 Succ. > Fine >>

Pag 7 di 3690